Skip to main content
Top
Published in: Drug Safety 3/2014

01-03-2014 | Original Research Article

Signalling Paediatric Side Effects using an Ensemble of Simple Study Designs

Authors: Jenna M. Reps, Jonathan M. Garibaldi, Uwe Aickelin, Daniele Soria, Jack E. Gibson, Richard B. Hubbard

Published in: Drug Safety | Issue 3/2014

Login to get access

Abstract

Background

Children are frequently prescribed medication ‘off-label’, meaning there has not been sufficient testing of the medication to determine its safety or effectiveness. The main reason this safety knowledge is lacking is due to ethical restrictions that prevent children from being included in the majority of clinical trials.

Objective

The objective of this paper is to investigate whether an ensemble of simple study designs can be implemented to signal acutely occurring side effects effectively within the paediatric population by using historical longitudinal data. The majority of pharmacovigilance techniques are unsupervised, but this research presents a supervised framework.

Methods

Multiple measures of association are calculated for each drug and medical event pair and these are used as features that are fed into a classifier to determine the likelihood of the drug and medical event pair corresponding to an adverse drug reaction. The classifier is trained using known adverse drug reactions or known non-adverse drug reaction relationships.

Results

The novel ensemble framework obtained a false positive rate of 0.149, a sensitivity of 0.547 and a specificity of 0.851 when implemented on a reference set of drug and medical event pairs. The novel framework consistently outperformed each individual simple study design.

Conclusion

This research shows that it is possible to exploit the mechanism of causality and presents a framework for signalling adverse drug reactions effectively.
Appendix
Available only for authorised users
Literature
1.
go back to reference Aagaard L, Christensen A, Hansen EH. Information about adverse drug reactions reported in children: a qualitative review of empirical studies. Br J Clin Pharmacol. 2010;70(4):481–91.PubMedCentralPubMedCrossRef Aagaard L, Christensen A, Hansen EH. Information about adverse drug reactions reported in children: a qualitative review of empirical studies. Br J Clin Pharmacol. 2010;70(4):481–91.PubMedCentralPubMedCrossRef
2.
go back to reference Conroy S, Choonara I, Impicciatore P, Mohn A, Arnell H, Rane A, Knoeppel C, Seyberth H, Pandolfini C, Raffaelli MP, et al. Survey of unlicensed and off label drug use in paediatric wards in European countries. Br Med J. 2000;320(7227):79–82.CrossRef Conroy S, Choonara I, Impicciatore P, Mohn A, Arnell H, Rane A, Knoeppel C, Seyberth H, Pandolfini C, Raffaelli MP, et al. Survey of unlicensed and off label drug use in paediatric wards in European countries. Br Med J. 2000;320(7227):79–82.CrossRef
3.
go back to reference Rose K, van den Anker JN. Guide to paediatric drug development and clinical research. Basel: Karger; 2010. Rose K, van den Anker JN. Guide to paediatric drug development and clinical research. Basel: Karger; 2010.
4.
go back to reference Bwakura-Dangarembizi M, Musesengwa R, Nathoo KJ, Takaidza P, Mhute T, Vhembo T. Ethical and legal constraints to childrens participation in research in Zimbabwe: experiences from the multicenter pediatric HIV ARROW trial. BioMed Central Med Ethics. 2012;13(1):17.CrossRef Bwakura-Dangarembizi M, Musesengwa R, Nathoo KJ, Takaidza P, Mhute T, Vhembo T. Ethical and legal constraints to childrens participation in research in Zimbabwe: experiences from the multicenter pediatric HIV ARROW trial. BioMed Central Med Ethics. 2012;13(1):17.CrossRef
5.
go back to reference Caldwell PH, Murphy SB, Butow PN, Craig JC. Clinical trials in children. Lancet. 2004;364(9436):803–11.PubMedCrossRef Caldwell PH, Murphy SB, Butow PN, Craig JC. Clinical trials in children. Lancet. 2004;364(9436):803–11.PubMedCrossRef
6.
go back to reference Lidz CW, Appelbaum PS, Grisso T, Renaud M. Therapeutic misconception and the appreciation of risks in clinical trials. Soc Sci Med. 2004;58(9):1689–97.PubMedCrossRef Lidz CW, Appelbaum PS, Grisso T, Renaud M. Therapeutic misconception and the appreciation of risks in clinical trials. Soc Sci Med. 2004;58(9):1689–97.PubMedCrossRef
7.
go back to reference Avery A, Anderson C, Bond C, Fortnum H, Gifford A, Hannaford P, Hazell L, Krska J, Lee A, McLernon D, et al. Evaluation of patient reporting of adverse drug reactions to the UK ‘Yellow card scheme’: Literature review, descriptive and qualitative analyses, and questionnaire surveys. Health Technol Assess. 2011;15(20):1–234. Avery A, Anderson C, Bond C, Fortnum H, Gifford A, Hannaford P, Hazell L, Krska J, Lee A, McLernon D, et al. Evaluation of patient reporting of adverse drug reactions to the UK ‘Yellow card scheme’: Literature review, descriptive and qualitative analyses, and questionnaire surveys. Health Technol Assess. 2011;15(20):1–234.
8.
go back to reference Aagaard L. Knowledge creation about adverse drug reactions in the paediatric population. Ugeskr Laeger. 2013;175(6):342–45.PubMed Aagaard L. Knowledge creation about adverse drug reactions in the paediatric population. Ugeskr Laeger. 2013;175(6):342–45.PubMed
9.
go back to reference Bate A, Evans S. Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf. 2009;18(6):427–36.PubMedCrossRef Bate A, Evans S. Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf. 2009;18(6):427–36.PubMedCrossRef
10.
go back to reference Ryan PB, Madigan D, Stang PE, Marc-Overhage J, Racoosin JA, Hartzema AG. Empirical assessment of methods for risk identification in healthcare data: results from the experiments of the Observational Medical Outcomes Partnership. Stat Med. 2012;31(30):4401–15.PubMedCrossRef Ryan PB, Madigan D, Stang PE, Marc-Overhage J, Racoosin JA, Hartzema AG. Empirical assessment of methods for risk identification in healthcare data: results from the experiments of the Observational Medical Outcomes Partnership. Stat Med. 2012;31(30):4401–15.PubMedCrossRef
11.
go back to reference Reps JM, Garibaldi JM, Aickelin U, Soria D, Gibson J, Hubbard R. Comparison of algorithms that detect drug side effects using electronic healthcare databases. Soft Comput. 2013;17(12):2381–97. doi:10.1007/s00500-013-1097-4. Reps JM, Garibaldi JM, Aickelin U, Soria D, Gibson J, Hubbard R. Comparison of algorithms that detect drug side effects using electronic healthcare databases. Soft Comput. 2013;17(12):2381–97. doi:10.​1007/​s00500-013-1097-4.
12.
go back to reference Jin H, Chen J, He H, Kelman C, McAullay D, O’Keefe CM. Signaling potential adverse drug reactions from administrative health databases. IEEE Trans Knowl Data Eng. 2010;22(6):839–53.CrossRef Jin H, Chen J, He H, Kelman C, McAullay D, O’Keefe CM. Signaling potential adverse drug reactions from administrative health databases. IEEE Trans Knowl Data Eng. 2010;22(6):839–53.CrossRef
13.
go back to reference Simpson SE. Self-controlled methods for postmarketing drug safety surveillance in large-scale longitudinal data. Ph.D. thesis, Columbia University; 2011. Simpson SE. Self-controlled methods for postmarketing drug safety surveillance in large-scale longitudinal data. Ph.D. thesis, Columbia University; 2011.
14.
go back to reference Harpaz R, DuMouchel W, Shah NH, Madigan D, Ryan P, Friedman C. Novel data-mining methodologies for adverse drug event discovery and analysis. Clin Pharmacol Ther. 2012;91(6):1010–21. Harpaz R, DuMouchel W, Shah NH, Madigan D, Ryan P, Friedman C. Novel data-mining methodologies for adverse drug event discovery and analysis. Clin Pharmacol Ther. 2012;91(6):1010–21.
15.
go back to reference Zorych I, Madigan D, Ryan P, Bate A. Disproportionality methods for pharmacovigilance in longitudinal observational databases. Stat Methods Med Res. 2013;22(1):39–56.PubMedCrossRef Zorych I, Madigan D, Ryan P, Bate A. Disproportionality methods for pharmacovigilance in longitudinal observational databases. Stat Methods Med Res. 2013;22(1):39–56.PubMedCrossRef
16.
go back to reference Norén GN, Hopstadius J, Bate A, Star K, Edwards IR. Temporal pattern discovery in longitudinal electronic patient records. Data Min Knowl Discov. 2010;20(3):361–87.CrossRef Norén GN, Hopstadius J, Bate A, Star K, Edwards IR. Temporal pattern discovery in longitudinal electronic patient records. Data Min Knowl Discov. 2010;20(3):361–87.CrossRef
17.
go back to reference Greenland S, Neutra R. Control of confounding in the assessment of medical technology. Int J Epidemiol. 1980;9(4):361–67.PubMedCrossRef Greenland S, Neutra R. Control of confounding in the assessment of medical technology. Int J Epidemiol. 1980;9(4):361–67.PubMedCrossRef
18.
go back to reference Reps JM, Garibaldi JM, Aickelin U, Soria D, Gibson JE, Hubbard RB. A novel prescription drug side effect classifier. IEEE Trans Knowl Data Eng. 2014 (submitted) Reps JM, Garibaldi JM, Aickelin U, Soria D, Gibson JE, Hubbard RB. A novel prescription drug side effect classifier. IEEE Trans Knowl Data Eng. 2014 (submitted)
19.
go back to reference Joint Formulary Committee. British National Formulary, 66 ed. London: BMJ Group and Pharmaceutical Press; 2013. Joint Formulary Committee. British National Formulary, 66 ed. London: BMJ Group and Pharmaceutical Press; 2013.
21.
go back to reference Overhage JM, Ryan PB, Reich CG, Hartzema AG, Stang PE. Validation of a common data model for active safety surveillance research. J Am Med Inf Assoc. 2012;19(1):54–60.CrossRef Overhage JM, Ryan PB, Reich CG, Hartzema AG, Stang PE. Validation of a common data model for active safety surveillance research. J Am Med Inf Assoc. 2012;19(1):54–60.CrossRef
Metadata
Title
Signalling Paediatric Side Effects using an Ensemble of Simple Study Designs
Authors
Jenna M. Reps
Jonathan M. Garibaldi
Uwe Aickelin
Daniele Soria
Jack E. Gibson
Richard B. Hubbard
Publication date
01-03-2014
Publisher
Springer International Publishing
Published in
Drug Safety / Issue 3/2014
Print ISSN: 0114-5916
Electronic ISSN: 1179-1942
DOI
https://doi.org/10.1007/s40264-014-0137-z

Other articles of this Issue 3/2014

Drug Safety 3/2014 Go to the issue